{'fraction_non_alphanumeric': 0.0395778364116095, 'fraction_numerical': 0.04309586631486367, 'mean_word_length': 4.776649746192893, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The In Vitro Evaluation of Modifications in CPD‐Adenine Anticoagulated‐Preserved Blood at Various Hematocrits

Erythrocytes stored in the new CPD‐adenine anticoagulant (CPDA‐1) barely met the 70 per cent 24‐hour postinfusion 51Cr recoveries on day 35 when stored at hematocrit ≥ 75 per cent. CPDA‐1 differs from CPD in that it has 1.25 times the glucose concentration plus 17.3 mg adenine/63 ml. In an effort to improve the survivability (or viability) of red blood cells following extended storage (35+ days), two new CPD‐adenine anticoagulants have been tested in vitro. CPDA‐2 and CPDA‐3 (both of which contain 34.6 mg/63 ml of anticoagulant or 0.50 mM adenine [final Mood concentration], and either 1.75 times or 2.0 times respectively the amount of glucose used in CPD) have been tested for whole blood or red blood cell storage to 42 days. Red blood cell ATP concentrations were better maintained throughout 42 days of storage in both of these formulations than in CPDA‐1 at hematocrits that ranged from 40 to 85. Other biochemical parameters (2,3‐DPG, pH, plasma hemoglobin) were similar to those of blood stored in CPD or CPDA‐1.